SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials. SS-31 is fda-approved september 2025 (forzinity) for barth syndrome. phase 3 trials ongoing for other indications. As with any research compound, individual responses vary.
Is SS-31 Safe?
Safety is the most important consideration with any research compound. SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide with a safety profile established through preclinical research.
FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
What Are the Known Side Effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
These effects are based on preclinical data and community reports at standard dosages of 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV. Higher doses generally increase both the likelihood and severity of side effects.
Are SS-31 Side Effects Dose-Dependent?
Most reported SS-31 side effects are dose-dependent — meaning they're more likely at higher doses and less likely at the lower end of the 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV range.
This is why starting at the minimum effective dose and titrating up is the standard approach. With a half-life of approximately 20-30 minutes, any adverse effects will typically resolve within a few half-life periods after discontinuation.
What About Long-Term SS-31 Use?
Long-term safety data for SS-31 is limited, as with most research peptides. Standard cycles run 12-48 weeks in clinical trials.
SS-31 is fda-approved september 2025 (forzinity) for barth syndrome. phase 3 trials ongoing for other indications. Extended use beyond recommended cycles should be approached with caution.
Does SS-31 Interact With Other Compounds?
Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways.
When stacking peptides, be aware that combining multiple compounds increases the total side-effect surface area. Monitor closely when introducing any new compound.
How Can You Minimize SS-31 Side Effects?
Start at the lower end of the dosage range (4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV). Use proper reconstitution and injection technique to minimize injection site reactions. Store correctly (lyophilized at -20°C, reconstituted at 2-8°C) to maintain purity.
Source only from vendors with third-party COA testing — contaminated or mislabeled products are a significant source of unexpected adverse effects.
What Is the Bottom Line on SS-31 Safety?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials. Overall, SS-31 is considered well-tolerated at standard research doses.
Read our SS-31 dosage guide for protocols designed to minimize risk.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
- MOTS-C Complete Guide
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.